Top 5 High Tech Companies To Buy Right Now

 

Caribbean (Photo credit: Moyan_Brenn)

Caribbean and Central American havens are often thought to be less rigorous in their observance of banking and tax laws than European nations like Switzerland. Of course, Swiss banking has experienced a sea change since UBS paid a $780 million fine and reached a deferred prosecution agreement with American authorities. With other Swiss bank closures and 14 Swiss banks still under investigation, everything is different now.

One by one, foreign governments and banks are lining up to take their medicine from the U.S. But what about Caribbean and Central American nations? The U.S. has pushed hard there too, including use of the pivotal John Doe summons here: IRS Issues John Doe Summonses To Citibank, Chase, BoA, Mellon, HSBC��ax Prosecutions Coming.

Top Sliver Companies For 2015: Washington Real Estate Investment Trust(WRE)

Washington Real Estate Investment Trust is an equity real estate investment trust (REIT). The company engages in the ownership, operation, and development of real properties. The firm invests in real estate markets of the greater Washington D.C. metro region. It focuses on office, medical office, industrial/flex space, retail, and multifamily real estate investments. Washington Real Estate Investment Trust was founded in 1960 and is based in Rockville, Maryland.

Advisors' Opinion:

• [By Rich Duprey]

  Commercial and residential income-producing property REIT�Washington Real Estate Investment Trust (NYSE: WRE  ) announced yesterday its third-quarter dividend of $0.30 per share, the same rate it's paid for the past four quarters.

Top 5 High Tech Companies To Buy Right Now: Isle of Capri Casinos Inc.(ISLE)

Isle of Capri Casinos, Inc., together with its subsidiaries, develops, owns, and operates gaming facilities and lodging and entertainment facilities in the United States. It owns and operates 14 casino gaming facilities located in Black Hawk, Colorado; Lake Charles, Louisiana; Lula, Biloxi, Natchez, and Vicksburg, Mississippi; Kansas City, Caruthersville, and Boonville, Missouri; Bettendorf, Davenport, Waterloo, and Marquette, Iowa; and Pompano Beach, Florida. The company?s properties feature approximately 15,000 slot machines; 370 table games, including 110 poker tables; 3,000 hotel rooms; and 40 restaurants. It also operates a harness racing track at its casino in Florida. Isle of Capri Casinos, Inc. was formerly known as Casino America, Inc. and changed its name to Isle of Capri Casinos, Inc. in October 1998. The company was founded in 1990 and is based in St Louis, Missouri.

Advisors' Opinion:

• [By Paul Ausick]

  The REIT is expected to spend as much as $500 million in acquisitions in 2014, according to Barron��, and some potential acquisition targets include Isle of Capri Casinos Inc. (NASDAQ: ISLE) which has a market cap of around $323 million or Dover Downs Gaming & Entertainment Inc. (NYSE: DDE) with a market cap of around $47 million.

Top 5 High Tech Companies To Buy Right Now: Unit Corporation(UNT)

Unit Corporation, together with its subsidiaries, engages in the contract drilling, oil and natural gas, and mid-stream businesses in the United States. The company?s Contract Drilling segment engages in land contract drilling of onshore oil and natural gas wells for oil and natural gas companies in Oklahoma, Texas, Louisiana, Wyoming, Colorado, Utah, Montana, and North Dakota. Its Oil and Natural Gas segment is involved in the acquisition, exploration, development, and production of oil and natural gas properties located primarily in Oklahoma, Texas, Louisiana, and North Dakota, as well as in Arkansas, New Mexico, Wyoming, Montana, Alabama, Kansas, Mississippi, Michigan, Colorado, Pennsylvania, and a small portion in Canada. As of December 31, 2011, this segment had approximately 121 gross proved undeveloped wells. The company?s Mid-Stream segment buys, sells, gathers, processes, and treats natural gas. It operates 3 natural gas treatment plants, 10 operating processing plants, 35 active gathering systems, and 934 miles of pipeline in Oklahoma, Texas, Kansas, Pennsylvania, and West Virginia. The company operates a fleet of 127 drilling rigs. Unit Corporation was founded in 1963 and is based in Tulsa, Oklahoma.

Advisors' Opinion:

• [By Robert Rapier]

  Having said that, I can’t find anything in the article archives about Unit Corp. (NYSE: UNT). Unit describes itself as a diversified energy company engaged in the exploration for and production of oil and natural gas, the acquisition of producing oil and natural gas properties, the contract drilling of onshore oil and natural gas wells, and the gathering and processing of natural gas.

Top 5 High Tech Companies To Buy Right Now: Onconova Therapeutics Inc (ONTX)

Onconova Therapeutics, Inc. (Onconova), incorporated on December 22, 1998, is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways, which promote cancer. It has three clinical-stage product candidates and six preclinical programs. Its preclinical pipeline includes six programs, which target kinases, cellular metabolism or division.

Rigosertib

Rigosertib, the Company�� product candidate, is being tested in a range of ongoing Phase-II and Phase-III clinical trials. The Company is conducting a pivotal phase-III trial of rigosertib under a Special Protocol Assessment (SPA), from the United States Food and Drug Administration (FDA), for higher risk myelodysplastic syndromes (MDS). The Company is also evaluating rigosertib in a Phase-III trial for metastatic pancreatic cancer, in two Phase-II trials for transfusion-dependent lower risk MDS, and in a Phase-II trial for head and neck cancers. Rigosertib has been granted orphan drug status for MDS in both the United States and Europe, as well as orphan drug status for pancreatic cancer in the United States. Baxter Healthcare SA (Baxter), a subsidiary of Baxter International Inc., has commercialization rights for rigosertib in Europe and SymBio Pharmaceuticals Limited (SymBio), has commercialization rights in Japan and Korea. Rigosertib is an inhibitor of two cellular signaling pathways: phosphoinositide 3-kinase (PI3K), and polo-like kinase (PLK), both of which are frequently over-active in cancer cells. By inhibiting the PI3K pathway in cancer cells, rigosertib promotes tumor cell apoptosis, or programmed cell death. It is testing both intravenous and oral formulations of rigosertib, referred to as rigosertib IV and rigosertib Oral, in clinical trials.

ON 013105

The Company�� clinical-stage product candidate, ON 013105, is i! n a Phase I trial in patients with relapsed or refractory lymphoma, including an aggressive form of non-Hodgkin's lymphoma identified as mantle cell lymphoma (MCL), and acute lymphoid leukemia (ALL). ON 013105 suppresses the accumulation of cyclin D1 in cancer cells.

Recilisib

The Company�� clinical-stage product candidate, recilisib, is being developed in collaboration with the United States Department of Defense (DoD), for acute radiation syndromes (ARS). The Company has completed four Phase-I trials to evaluate the safety and pharmacokinetics of recilisib in healthy human adult subjects using both subcutaneous and oral formulations, referred to as recilisib SC and recilisib Oral.

Preclinical Programs

The Company�� ON 1231320 is a specific inhibitor of Polo-like Kinase 2 (PLK2), and in preclinical studies, it induced mitotic arrest and reduced tumor burden in mice injected subcutaneously with colon tumor and triple-negative breast cancer cells. The Company�� ON 123300 inhibits the activity of two kinases, cyclin-dependent kinase 4 (CDK4), and AMP-activated protein kinase 5 (ARK5). Its ON 108600 is a dual inhibitor of two growth-regulatory kinases. Cyclin-dependent kinase 9 is over expressed in several cancers, including leukemias and lymphomas. Casein kinase 2 is overexpressed in a range of tumor types. ON 044580 inhibits mutant forms of the two target kinases, including Janus Kinase 2 (JAK2) and imatinib-resistant Bcr-Abl Kinase (Bcr-Abl). Its ON 24 compounds cause tubulin to depolymerize, inducing mitotic arrest in cultured tumor cell lines. Its ON 146040 inhibits the growth of a range of blood cancer cell lines, including Burkitt's lymphoma, MCL, multiple myeloma and chronic myeloid leukemia.

The Company competes with Eisai Inc., Celgene Corporation, Genentech, Inc., Cell Therapeutics, Inc., Cyclacel Pharmaceuticals, Inc., Telik, Inc., Spectrum Pharmaceuticals, Inc., Astex, Array BioPharma Inc., Astellas Pharma, Inc., Threshold! Pharmace! uticals, Inc., Pharmacyclics Inc., Soligenix, Inc., Cellerant Therapeutics, Inc. and Cleveland BioLabs, Inc.

Advisors' Opinion:

• [By Roberto Pedone]

   

  One under-$10 clinical-state biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Onconova Therapeutics (ONTX), which focuses on discovering and developing small molecule drug candidates to treat cancer. This stock has been destroyed by the short-sellers so far in 2014, with shares off sharply by 56%.

   

  If you glance at the chart for Onconova Therapeutics, you'll notice that this stock has been trending sideways and consolidating right below its 50-day moving average for the last few weeks. This consolidation pattern is occurring right after shares of ONTX recently spiked sharply higher from its low of $4.10 to its high of $5.52 a share. Shares of ONTX are now trending within range of breaking out of that consolidation pattern and potentially heading higher.

   

  Traders should now look for long-biased trades in ONTX if it manages to break out above its 50-day moving average of $5.09 a share and then once it takes out some more key overhead resistance levels at $5.24 to $5.52 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 203,756 shares. If that breakout triggers soon, then ONTX will set up to re-test or possibly take out its next major overhead resistance levels at $6.27 to $7 a share.

   

  Traders can look to buy ONTX off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.75 to right around $4.50 a share. One can also buy ONTX off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

   

• [By Roberto Pedone]

   

  Onconova Therapeutics (ONTX), a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. This stock closed up 2.5% to $5.15 in Thursday's trading session.

   

  Thursday's Range: $4.97-$5.19
  
  52-Week Range: $4.10-$31.13
  
  Thursday's Volume: 132,000
  
  Three-Month Average Volume: 216,102

   

  From a technical perspective, ONTX trended modestly higher here with lighter-than-average volume. This stock has been uptrending over the last few weeks, with shares moving higher from its low of $4.10 to its recent high of $5.52. During that uptrend, shares of ONTX have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of ONTX within range of triggering a near-term breakout trade. That trade will hit if ONTX manages to take out Thursday's intraday high of $5.19 to some more key overhead resistance at $5.52 with high volume.

   

  Traders should now look for long-biased trades in ONTX as long as it's trending above some near-term support levels at $4.80 or at $4.50 and then once it sustains a move or close above those breakout levels with volume that hits near or above 216,102 shares. If that breakout gets underway soon, then ONTX will set up to re-test or possibly take out its next major overhead resistance levels at $5.83 to $6.27. Any high-volume move above those levels will then give ONTX a chance to tag $7.

   

• [By gurujx]

  Onconova Therapeutics Inc (ONTX) Reached the 3-year Low of $4.18

  The prices of Onconova Therapeutics Inc (ONTX) shares have declined to close to the 3-year low of $4.18, which is 86.8% off the 3-year high of $31.13.